Dunaieva I. P.
CARDIOMETABOLIC PHENOTYPES IN PATIENTS WITH ARTERIAL HYPERTENSION, TYPE 2 DIABETES MELLITUS AND OBESITY AND THEIR KEY INDICATORS
Show/Download
About the author:
Dunaieva I. P.
Heading:
CLINICAL AND EXPERIMENTAL MEDICINE
Type of article:
Scientific article
Annotation:
This paper examines the peculiarities of cardiometabolic phenotypes in patients with arterial hypertension, type 2 diabetes mellitus, and obesity. The key markers reflecting changes in the cardiovascular and renal systems, including cardiotrophin-1, catestatin, and neutrophil gelatinase-associated lipocalin, were identified. This study was aimed at identifying the peculiarities of cardiometabolic phenotypes and early markers of pathology development in patients with combined conditions of arterial hypertension, type 2 diabetes mellitus, and obesity. 211 patients were included in the study, divided into four groups depending on comorbidity. Clinical, laboratory, and instrumental techniques, including analysis of lipid and carbohydrate profiles, as well as levels of heart failure markers, and assessment of heart structure and function using ultrasound diagnostics were used. Three cardiometabolic phenotypes of patients were identified depending on comorbidity. The levels of such markers as cardiotrophin-1, NT-proBNP, and NGAL were found to be significantly correlated with the risk of cardiovascular and renal impairment. Patients with combined pathology exhibit the most pronounced disorders. It was established that developing individualized approaches to diagnosis and therapy based on cardiometabolic phenotypes can contribute to the early detection of complications and reduce cardiovascular risk in patients with comorbidities.
Tags:
Bibliography:
- Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2020;76(17):2192-2208.
- House AA, Anand I, Bellomo R, Cruz DN, Daliento L, Ronco C. Heart failure in patients with chronic kidney disease: The cardiorenal connection. Am J Kidney Dis. 2019;74(2):240-257.
- Damman K, Valente MAE, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Cardiorenal syndrome in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol. 2021;18(8):481-495.
- Bock JS, Gottlieb SS. Cardiorenal syndrome: New perspectives. Circulation. 2020;121(23):2592-2600.
- McCullough PA, Nowak RM, Foreback C, Tokarczyk B, Tomlanovich MC. Consensus on AKI biomarkers and cardiorenal syndromes. Nephrol Dial Transplant. 2020;35(2):239-254.
- Gheorghiade M, Braunwald E. The role of the kidney in heart failure. Eur Heart J. 2019;40(12):979-981.
- Ronco C, Bellomo R. Cardiorenal syndromes: Report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J. 2020;41(22):2040-2049.
- Packer M. Critical reappraisal of the role of inflammation in heart failure and cardiorenal syndrome. Am J Cardiol. 2020;125(5):755-759.
- Crespo-Leiro MG, Anker SD, Coats AJ, Fonarow GC, Lopez-Sendon J, McMurray JJ, et al. Advanced heart failure: A position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;20(11):1505-1535.
- Kotecha D, Manzano L, Kalogeropoulos AP, Georgiopoulou VV, Butler J. Epidemiology and outcomes of cardiorenal syndromes in patients with heart failure: A systematic review and meta-analysis. J Am Heart Assoc. 2022;11(3):e022354.
- Di Lullo L, Bellasi A, Barbera V, Russo D, Cozzolino M, Ronco C. Pathophysiology of the cardiorenal syndromes types 1-5: An update. Indian Heart J. 2021;73(2):189-207.
- Bansal N, Zelnick LR, Bhat Z, Gupta DK, Guddeti RR. Cardiorenal syndrome: A review for clinicians. Mayo Clin Proc. 2021;96(3):748-762.
Publication of the article:
«Bulletin of problems biology and medicine», 2024 Issue 4, 175, 349-361 pages, index UDC 616.12-008.331.1:616.379-008.64]-056.25-078-085
